GlobeNewswire
Dublin, April 23, 2021 (GLOBE NEWSWIRE) -- The "Next Generation Cancer Diagnostics Market Research Report by Technology, by Cancer Type, by Function, by Application - Global Forecast to 2025 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering. The Global Next Generation Cancer Diagnostics Market is expected to grow from USD 5,693.79 Million in 2020 to USD 15,738.27 Million by the end of 2025.Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Next Generation Cancer Diagnostics Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.The report answers questions such as:1. What is the market size and forecast of the Global Next Generation Cancer Diagnostics Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Next Generation Cancer Diagnostics Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Next Generation Cancer Diagnostics Market?4. What is the competitive strategic window for opportunities in the Global Next Generation Cancer Diagnostics Market?5. What are the technology trends and regulatory frameworks in the Global Next Generation Cancer Diagnostics Market?6. What are the modes and strategic moves considered suitable for entering the Global Next Generation Cancer Diagnostics Market?Key Topics Covered: 1. Preface2. Research Methodology3. Executive Summary3.1. Introduction3.2. Market Outlook3.3. Cancer Type Outlook3.4. Technology Outlook3.5. Function Outlook3.6. Application Outlook3.7. Geography Outlook3.8. Competitor Outlook4. Market Overview4.1. Introduction4.2. Cumulative Impact of COVID-195. Market Insights5.1. Market Dynamics5.1.1. Drivers5.1.1.1. Rising incidence of oncology diseases5.1.1.2. Significantly decreasing cost of genetic sequencing5.1.1.3. Benefits of cluster chip technology and applications of CTC in cancer management5.1.2. Restraints5.1.2.1. Need for expensive laboratory set-up5.1.2.2. Insufficient reimbursement policies for innovative technologies5.1.3. Opportunities5.1.3.1. Government support in a number of research projects in oncology and preventative diagnosis5.1.3.2. Potential CTC enumeration sectors to monitor tumorigenesis5.1.4. Challenges5.1.4.1. Shortage of helium and increased cost of diagnostic imaging systems5.2. Porters Five Forces Analysis6. Global Next Generation Cancer Diagnostics Market, By Technology6.1. Introduction6.2. DNA Microarrays6.3. Lab-on- a- chip & Reverse Transcriptase-PCR6.4. Next Generation Sequencing6.5. Protein Microarrays6.6. qPCR & Multiplexing7. Global Next Generation Cancer Diagnostics Market, By Cancer Type7.1. Introduction7.2. Breast Cancer7.3. Cervical Cancer7.4. Colorectal Cancer7.5. Lung Cancer8. Global Next Generation Cancer Diagnostics Market, By Function8.1. Introduction8.2. Cancer Screening8.3. Companion Diagnostics8.4. Prognostics8.5. Risk Analysis8.6. Therapeutic Monitoring9. Global Next Generation Cancer Diagnostics Market, By Application9.1. Introduction9.2. Biomarker Development9.3. CTC Analysis9.4. Epigenetic Analysis9.5. Genetic Analysis9.6. Proteomic Analysis10. Americas Next Generation Cancer Diagnostics Market11. Asia-Pacific Next Generation Cancer Diagnostics Market12. Europe, Middle East & Africa Next Generation Cancer Diagnostics Market13. Competitive Landscape13.1. FPNV Positioning Matrix13.2. Market Ranking Analysis13.3. Market Share Analysis13.4. Competitor SWOT Analysis13.5. Competitive Scenario14. Company Usability Profiles14.1. Abbott Laboratories14.2. Adaptive Biotechnologies Inc.14.3. Agendia Nv14.4. Agilent Technologies, Inc14.5. Akadeum Life Sciences14.6. Almac Group14.7. Ambry Genetics14.8. Becton, Dickinson And Co.14.9. Biological Dynamics Inc.14.10. Castle Biosciences Inc.14.11. Danaher Corporation14.12. Exosome Diagnostics, Inc.14.13. F. Hoffmann-La Roche Ltd14.14. GE Healthcare14.15. Genomic Health, Inc.14.16. Hologic, Inc14.17. Illumina, Inc.14.18. Janssen Global Services, LLC14.19. Koninklijke Philips N.V.14.20. Myriad Genetics, Inc.14.21. Novartis AG14.22. Opko Health, Inc.14.23. Perkin Elmer, Inc.14.24. Qiagen N.V.14.25. Sysmex Corporation14.26. Thermo Fisher Scientific, Inc. For more information about this report visit https://www.researchandmarkets.com/r/5aee8w CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900